-
Mashup Score: 14LARVOL - 2 month(s) ago
AI in Oncology | @LARVOL Onco Data Podcast with @HSaterMD
Source: twitter.comCategories: General Medicine NewsTweet
-
Mashup Score: 11Cancer Trial Results - 2 month(s) ago
Clin Larvol | Cancer Trial Results
Source: clin.larvol.comCategories: General Medicine NewsTweet
-
Mashup Score: 10Cancer Trial Results - 2 month(s) ago
Clin Larvol | Cancer Trial Results
Source: clin.larvol.comCategories: General Medicine NewsTweet
-
Mashup Score: 3Dr. Vinay Prasad's Views on Key ASCO Breast Cancer Trials - 2 month(s) ago
Dr. Vinay Prasad is now Director of FDA’s CBER Division, Review his thoughts on NATALEE, DESTINY-Breast04, and postMONARCH breast cancer clinical trials
Source: kolpulse.comCategories: General Medicine NewsTweet
-
Mashup Score: 7LARVOL - 2 month(s) ago
Pre – #ASCO25 | LARVOL CLIN – Building in public: Episode 32
Source: twitter.comCategories: General Medicine NewsTweet
-
Mashup Score: 5Are We at the End of Ai Progress— With Gary Marcus - 2 month(s) ago
Gary Marcus is a cognitive scientist, author, and longtime AI skeptic.Gary joins Big Technology to discuss why large‑language‑model scaling is running into a…
Source: www.youtube.comCategories: General Medicine NewsTweet
-
Mashup Score: 12Cancer Trial Results - 2 month(s) ago
Clin Larvol | Cancer Trial Results
Source: clin.larvol.comCategories: General Medicine NewsTweet
-
Mashup Score: 5Treatment of Pleural Mesothelioma: ASCO Guideline Clinical Insights | JCO Oncology Practice - 4 month(s) ago
Scheduled maintenance Monday, March 10, 2025. Please note that new registrations and purchases will be unavailable on this date. There has been considerable progress in the management of pleural mesothelioma since the initial ASCO clinical practice guideline was published in 2018. 1 Updated evidence-based recommendations were developed to reflect the new data published since the 2018 guideline, focusing on four key areas: the role of surgery, new systemic treatments, pathologic insights, and germline
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Long-Term Survival by ICIs in PD-L1–Negative Metastatic NSCLC - 5 month(s) ago
This systematic review and meta-analysis evaluates long-term survival outcomes by number of immune checkpoint inhibitors among patients with programmed death-ligand 1 (PD-L1)–negative non–small cell lung cancer (NSCLC).
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 15Program Guide – ASCO Meeting Program Guide - 5 month(s) ago
Bixia Tang , Xinan Sheng , Jun Guo , Haitao Niu , Yali Shen , Shusuan Jiang , Bin Fu , Jianming Guo , Wasilijiang Wahafu , Kai Yao , Nan Liu , Jiang Gu , Yu Chen , Zhenhua Li , Tianxin Lin , Liping Ma , Jiaqin Lin , Chi Zhang , Wenliang Wang Beijing Cancer Hospital, Peking University, The Affiliated Hospital of Qingdao University, West China Hospital, Sichuan University, Hunan Cancer Hospital, The First Affiliated Hospital of Nanchang University, Zhongshan Hospital, Fudan University, Shanxi Provincial
Source: meetings.asco.orgCategories: General Medicine News, Hem/OncsTweet
RT @Larvol: AI in Oncology | @LARVOL Onco Data Podcast with @HSaterMD https://t.co/nxt1XHCjbB